Dalsan You1, Chunwoo Lee2, In Gab Jeong1, Cheryn Song1, Jae-Lyun Lee3, Bumsik Hong1, Jun Hyuk Hong1, Hanjong Ahn1, Choung-Soo Kim4. 1. Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Korea. 2. Department of Urology, Gyeongsang National University Changwon Hospital, Gyeongsang National University School of Medicine, Changwon, Gyeongsangnam, Korea. 3. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. 4. Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Korea. cskim@amc.seoul.kr.
Abstract
PURPOSE: We evaluated the value of metastasectomy in patients treated with targeted therapy for metastatic renal cell carcinoma (mRCC). METHODS: The medical records of 325 patients who presented with mRCC were reviewed; among these patients, 33 underwent complete metastasectomy followed by targeted therapy (complete metastasectomy group), 29 underwent incomplete metastasectomy followed by targeted therapy (incomplete metastasectomy group), and 263 treated with targeted therapy alone (non-metastasectomy group). We estimated progression-free and overall survivals using Kaplan-Meier curves. A Cox proportional hazards regression model was used to estimate the prognostic significance of metastasectomy. RESULTS: Clinicopathological variables did not differ among the three groups except for age, history of nephrectomy, type of metastasis, the International Metastatic Renal Cell Carcinoma Database Consortium risk groups, histology, and bone metastasis. The median progression-free survivals were 29.5, 18.8, and 14.8 months in the complete, incomplete, and non-metastasectomy groups (p < 0.001). Complete metastasectomy (hazard ratio 0.431, p = 0.001) was an independent predictor of disease progression, along with targeted agents, risk groups, sarcomatoid feature, and number of metastatic sites. The median overall survivals were 92.5, 29.6, and 23.5 months in the complete, incomplete, and non-metastasectomy groups (p < 0.001). Complete metastasectomy (hazard ratio 0.378, p = 0.001) was an independent predictor of overall survival, along with targeted agents, type of metastasis, risk groups, sarcomatoid feature, and number of metastatic sites. CONCLUSIONS: Complete metastasectomy performed before targeted therapy might improve progression-free and overall survivals in patients with mRCC.
PURPOSE: We evaluated the value of metastasectomy in patients treated with targeted therapy for metastatic renal cell carcinoma (mRCC). METHODS: The medical records of 325 patients who presented with mRCC were reviewed; among these patients, 33 underwent complete metastasectomy followed by targeted therapy (complete metastasectomy group), 29 underwent incomplete metastasectomy followed by targeted therapy (incomplete metastasectomy group), and 263 treated with targeted therapy alone (non-metastasectomy group). We estimated progression-free and overall survivals using Kaplan-Meier curves. A Cox proportional hazards regression model was used to estimate the prognostic significance of metastasectomy. RESULTS: Clinicopathological variables did not differ among the three groups except for age, history of nephrectomy, type of metastasis, the International Metastatic Renal Cell Carcinoma Database Consortium risk groups, histology, and bone metastasis. The median progression-free survivals were 29.5, 18.8, and 14.8 months in the complete, incomplete, and non-metastasectomy groups (p < 0.001). Complete metastasectomy (hazard ratio 0.431, p = 0.001) was an independent predictor of disease progression, along with targeted agents, risk groups, sarcomatoid feature, and number of metastatic sites. The median overall survivals were 92.5, 29.6, and 23.5 months in the complete, incomplete, and non-metastasectomy groups (p < 0.001). Complete metastasectomy (hazard ratio 0.378, p = 0.001) was an independent predictor of overall survival, along with targeted agents, type of metastasis, risk groups, sarcomatoid feature, and number of metastatic sites. CONCLUSIONS: Complete metastasectomy performed before targeted therapy might improve progression-free and overall survivals in patients with mRCC.
Authors: R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford Journal: N Engl J Med Date: 2001-12-06 Impact factor: 91.245
Authors: Toni K Choueiri; Wanling Xie; Christian Kollmannsberger; Scott North; Jennifer J Knox; J Geoffrey Lampard; David F McDermott; Brian I Rini; Daniel Y C Heng Journal: J Urol Date: 2010-11-12 Impact factor: 7.450
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Bradley C Leibovich; John C Cheville; Christine M Lohse; Horst Zincke; Igor Frank; Eugene D Kwon; Jaime R Merchan; Michael L Blute Journal: J Urol Date: 2005-11 Impact factor: 7.450
Authors: Saeed Dabestani; Lorenzo Marconi; Fabian Hofmann; Fiona Stewart; Thomas B L Lam; Steven E Canfield; Michael Staehler; Thomas Powles; Börje Ljungberg; Axel Bex Journal: Lancet Oncol Date: 2014-10-26 Impact factor: 41.316
Authors: Daniel Y C Heng; J Connor Wells; Brian I Rini; Benoit Beuselinck; Jae-Lyun Lee; Jennifer J Knox; Georg A Bjarnason; Sumanta Kumar Pal; Christian K Kollmannsberger; Takeshi Yuasa; Sandy Srinivas; Frede Donskov; Aristotelis Bamias; Lori A Wood; D Scott Ernst; Neeraj Agarwal; Ulka N Vaishampayan; Sun Young Rha; Jenny J Kim; Toni K Choueiri Journal: Eur Urol Date: 2014-06-13 Impact factor: 20.096
Authors: John M L Ebos; Christina R Lee; James G Christensen; Anthony J Mutsaers; Robert S Kerbel Journal: Proc Natl Acad Sci U S A Date: 2007-10-17 Impact factor: 11.205
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Oliver Beetz; Rabea Söffker; Sebastian Cammann; Felix Oldhafer; Florian W R Vondran; Florian Imkamp; Jürgen Klempnauer; Moritz Kleine Journal: Langenbecks Arch Surg Date: 2020-01-14 Impact factor: 3.445